A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, health watchdog NICE says. Report by Lillya. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
